Skip to main content

Structure Therapeutics Inc.

corporate_fare Company Profile

Structure Therapeutics Inc.

GPCR·NASDAQ·Life Sciences·CIK 0001888886

We are a clinical-stage global biopharmaceutical company developing new oral small molecule drugs to treat various chronic diseases where current treatments are insufficient. Our technology platform uses structure-based drug discovery and computational chemistry to find and develop small molecule drugs that target G-protein coupled receptors (GPCRs). These receptors control many different body processes, and about one-third of all marketed medicines target GPCR-related pathways for conditions like metabolic, cardiovascular, and pulmonary disorders. Our most advanced drug candidate is aleniglipron (also known as GSBR-1290), an oral small molecule that activates the glucagon-like-peptide-1 receptor (GLP-1R). It is currently in five ongoing clinical studies for treating obesity, overweight, and related conditions. We also have two oral small molecule amylin receptor activators: ACCG-2671, which is in Phase 1 clinical development, and ACCG-3535, which is our second amylin development candidate. Our obesity pipeline also includes several preclinical small molecules targeting glucose-dependent insulinotropic polypeptide and glucagon receptors. These programs could be developed as single treatments or in fixed-dose combinations with our GLP-1 or amylin candidates. These combinations could address diseases beyond obesity, such as type 2 diabetes mellitus (T2DM), heart failure, sleep apnea, chronic kidney disease, osteoarthritis, metabolic dysfunction-associated steatotic liver disease (MASH), and potentially addiction, Parkinson's disease, and Alzheimer's disease. As oral small molecules, our candidates may be more accessible than biologic and peptide therapies, potentially offering different efficacy and safety, and are more scalable to manufacture for global demand.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for GPCR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-11, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for GPCR spans 10-Q, 8-K, 424B5, 10-K.

Recent high-impact activity:

  • Structure Therapeutics Posts $1.98/Share Q3 Loss, Nearly Triple the 58-Cent Consensus
  • Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028
  • Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028
  • Aleniglipron Shows 16.2% Weight Loss at 72 Weeks, CEO Touts Safety and Cost Edge
  • Positive Phase 1/2a and 72-Week OLE Data Reported Across Oral Amylin and GLP-1 Programs

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$141.2M
Diluted EPS
-$0.80
Op. Cash Flow
-$222.2M
Free Cash Flow
-$225.81M
Operating Income
-$176.56M
Cash & Equivalents
$799.62M
Debt / Equity
0.00×
Shares Outstanding
212.51M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020562

Short Interest & Short Volume

6.50 days to cover

FINRA reported short interest of 5,927,622 shares in GPCR as of the October 30, 2026 settlement, a 17.1% decrease from the prior period — about 6.5 days to cover at its recent average daily volume. On November 19, 2026, 40.7% of GPCR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,927,622 shares as of October 30, 2026
Change vs prior period▼ 17.1%
Days to cover6.50 at avg daily volume of 911,823
Daily short volume (FINRA facilities)40.7% of 257,125 shares on November 19, 2026
5-day average short volume38.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with G →
$16.23 -5.23% today
52-week range · as of 2026-11-09 $16.23 – $94.9
Market cap
$1.22B
Volume
638.8K (0.6× avg)
3-mo avg 1M
Live data · 2026-11-20 20:50 UTC · Market open

show_chartPrice Chart

Loading chart...

feed GPCR - Latest Insights

GPCR
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $20.95
Real-time Price: $16.23 info
Change: -$4.72 (-23%) info
Market Cap: $1.222B info
GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $16.23 info
Change: -$5.18 (-24%) info
Market Cap: $1.222B info
GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $16.23 info
Change: -$5.18 (-24%) info
Market Cap: $1.222B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $16.23 info
Change: -$20.56 (-56%) info
Market Cap: $1.222B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $16.23 info
Change: -$31.38 (-66%) info
Market Cap: $1.222B info
GPCR
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $47.50
Real-time Price: $16.23 info
Change: -$31.28 (-66%) info
Market Cap: $1.222B info
GPCR
Aug 06, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.62
Real-time Price: $16.23 info
Change: -$36.39 (-69%) info
Market Cap: $1.222B info
GPCR
Jun 05, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $38.00
Real-time Price: $16.23 info
Change: -$21.78 (-57%) info
Market Cap: $1.222B info
GPCR
May 07, 2026, 5:25 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $39.35
Real-time Price: $16.23 info
Change: -$23.13 (-59%) info
Market Cap: $1.222B info
GPCR
May 07, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $39.35
Real-time Price: $16.23 info
Change: -$23.13 (-59%) info
Market Cap: $1.222B info
GPCR
May 07, 2026, 4:17 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $39.35
Real-time Price: $16.23 info
Change: -$23.13 (-59%) info
Market Cap: $1.222B info
GPCR
May 04, 2026, 4:02 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $43.04
Real-time Price: $16.23 info
Change: -$26.81 (-62%) info
Market Cap: $1.222B info
GPCR
Apr 15, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $54.13
Real-time Price: $16.23 info
Change: -$37.91 (-70%) info
Market Cap: $1.222B info
GPCR
Mar 16, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $59.13
Real-time Price: $16.23 info
Change: -$42.91 (-73%) info
Market Cap: $1.222B info
GPCR
Mar 16, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $58.00
Real-time Price: $16.23 info
Change: -$41.78 (-72%) info
Market Cap: $1.222B info
GPCR
Feb 26, 2026, 4:40 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $64.76
Real-time Price: $16.23 info
Change: -$48.54 (-75%) info
Market Cap: $1.222B info
GPCR
Feb 26, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $64.75
Real-time Price: $16.23 info
Change: -$48.53 (-75%) info
Market Cap: $1.222B info
GPCR
Jan 05, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.77
Real-time Price: $16.23 info
Change: -$46.55 (-74%) info
Market Cap: $1.222B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets